Evidence map›Paper›PMID 42558240›Full record

ArticleFrontiers in oncology2026

Development and internal validation of a parsimonious logistic regression model integrating multiparametric clinical indicators for predicting prostate cancer in the PI-RADS 3 cohort.

Yongheng Zhou, Meikai Zhu, Yang Zheng, Wenfu Wang, Yaofeng Zhu

Abstract read
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yongheng Zhou *Department of Urology, Qilu Hospital of Shandong University, Jinan, China.
Meikai Zhu *Department of Urology, Qilu Hospital of Shandong University, Jinan, China.
Yang ZhengDepartment of Urology, Qilu Hospital of Shandong University, Jinan, China.
Wenfu WangDepartment of Urology, Qilu Hospital of Shandong University, Jinan, China.
Yaofeng ZhuDepartment of Urology, Qilu Hospital of Shandong University, Jinan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To develop and internally validate a parsimonious logistic regression model for clinically significant prostate cancer (CSPCa) specifically in patients with PI-RADS 3 lesions, integrating multiparametric clinical indicators to guide biopsy decision-making. Methods: We retrospectively enrolled 193 patients with PI-RADS 3 lesions who underwent mpMRI and prostate biopsy. A nested five-fold cross-validation framework was used, with LASSO regression performed independently in each training fold to select predictors from nine clinical variables. Four modeling approaches were compared, and logistic regression was chosen as the final model based on performance, calibration, and interpretability. Model discrimination, calibration, and clinical utility were evaluated internally. Results: LASSO selected age, PHI, and PHID as core predictors. Logistic regression achieved the highest cross-validated AUROC (0.840, 95% CI: 0.754-0.916) with acceptable calibration (slope 0.917, intercept -0.122). The model outperformed PSA and PSAD alone, and showed numerically higher discrimination than PHI or PHID alone. However, the incremental AUROC gain over PHI or PHID alone did not reach statistical significance. Exploratory risk stratification identified low-, intermediate-, and high-risk groups with CSPCa detection rates of 8.1%, 38.5%, and 83.3%, respectively. Conclusion: A three-variable logistic model incorporating age, PHI, and PHID demonstrated stable internal performance for predicting CSPCa in PI-RADS 3 patients. External validation is needed before clinical implementation.

Indexed as

diagnosismachine learningmultiparametric clinical indicatorsPI-RADS 3prostate cancer

Identifiers

PMID42558240
PMCPMC13437321

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.